 Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: SD-101 in combination with pembrolizumab in recurrent/metastatic squamous cell carcinoma

Clin Cancer Res: SD-101 in combination with pembrolizumab in recurrent/metastatic squamous cell carcinoma

 Last Update: 2022-03-04
 Source: Internet
 Author: User

Tags

responses

pd l1 expression

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

The prognosis for recurrent and metastatic squamous cell carcinoma (HNSCC) was poor until the advent of immune checkpoint inhibitors, particularly PD-1 antibodies
.

Median overall survival was approximately 10 months with platinum, 5-fluorouracil, and cetuximab as standard first-line therapy, but more than 80% of patients experienced grade 3 or higher treatment-related adverse events

immunity

SD-101 is a synthetic Toll-like receptor 9 agonist that stimulates human plasmacytoid dendritic cells to release IFNa and mature into highly efficient antigen-presenting cells, enhancing innate and adaptive immune responses
.

This study aimed to investigate whether SD-101 could enhance the anti-tumor activity of anti-PD-1 antibodies in anti-PD-1/PD-L1-naïve patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)
.

Anti-PD-1/PD-L1-naïve patients with recurrent/metastatic head and neck squamous cell carcinoma received weekly injections of SD-101 (2 mg into 1-4 lesions, or 8 mg into one lesion; After 4 times, it will be changed to once every 3 weeks, and then 7 times)
.

In addition, pembrolizumab 200 mg every 3 weeks

A total of 28 patients received 2 mg SD-101 and 23 patients received 8 mg SD-101
.

Overall, 76% of patients had previous systemic therapy

clinical prognosis

Twelve patients experienced grade ≥3 treatment-related adverse reactions (24%), but no treatment-related deaths
.

The objective response rate was 24%, including two complete responses and 10 partial responses

Adverse reactions

HPV-positive patients had the highest response rate (44%, n=16)
.

There was no significant correlation between remission and baseline PD-L1 expression level and IFNγ-related gene expression

HPV-positive patients had the highest response rate (44%, n=16) HPV-positive patients had the highest response rate (44%, n=16)

In conclusion, SD-101 combined with pembrolizumab induces objective responses in PD-1 antibody-naïve patients with recurrent/metastatic squamous cell carcinoma , especially HPV-positive tumors

SD-101 combined with pembrolizumab can induce PD-1 antibody-naïve patients with recurrent/metastatic squamous cell carcinoma achieve objective response SD-101 combined with pembrolizumab can induce PD-1 antibody- naïve relapse/metastatic Objective response in patients with metastatic squamous cell carcinoma

Original source:

Ezra EW Cohen, Lisle Nabell, Deborah J.

Intralesional SD-101 in Combination with Pembrolizumab in Anti-PD-1 Treatment-Na?ve Head and Neck Squamous Cell Carcinoma: Results from a Multicenter, Phase II Trial

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.